Literature DB >> 2838321

Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin.

M Höyhtyä1, T Turpeenniemi-Hujanen, W Stetler-Stevenson, H Krutzsch, K Tryggvason, L A Liotta.   

Abstract

Type IV collagenase is a metalloproteinase associated with metastatic tumor cells. It specifically cleaves the triple helical basement membrane (type IV) collagen molecule at a single site. Monoclonal antibodies which block the activity of the human type IV collagenase were developed and used to purify this antigen. The purified type IV collagenase was partially sequenced following cyanogen bromide and trypsin cleavage. The amino acid sequence of the human type IV collagenase fragments revealed a region homologous to the human interstitial collagenase and stromelysin. However, several sequences in type IV collagenase were identified which are distinct from the latter. Polyclonal antibodies were raised against a synthetic peptide derived from such a sequence. Following affinity purification, the antibodies recognized the denatured human type IV collagenase in Western immunoblotting. These data indicate that type IV collagenase is a distinct member of a general family of metalloproteinases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838321     DOI: 10.1016/0014-5793(88)81365-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

Review 1.  Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.

Authors:  Ajay Kumar Chaudhary; Mamta Singh; Alok C Bharti; Kamlesh Asotra; Shanthy Sundaram; Ravi Mehrotra
Journal:  J Biomed Sci       Date:  2010-02-15       Impact factor: 8.410

2.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

Authors:  Z S Galis; G K Sukhova; M W Lark; P Libby
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.